ArticleVirchows Archiv : an international journal of pathology2025
Novel HSPA8-NR4A2 rearrangement in extraskeletal myxoid chondrosarcoma: a sarcoma mimicker of neuroendocrine neoplasia.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Extraskeletal myxoid chondrosarcoma (EMC) is a rare mesenchymal neoplasm of uncertain differentiation associating with diagnostic NR4A3 gene rearrangements. An unusual case of EMC harboring the novel HSPA8::NR4A2 gene fusion and neuroendocrine phenotype is described. The tumor exhibited a lobular architecture, myxoid stroma, and epithelioid tumor cells with a complete neuroendocrine phenotype by specific immunohistochemistry and transmission electron microscopy. The lesions showed a low tumor mutational burden (1.9 muts/Mb), a microsatellite stable status, no cancer driver gene mutations, no canonical NR4A3 fusion and low copy number variation. A novel in-frame fusion between HSPA8 (exon 2) and NR4A2 (exon 3) was identified by RNA-sequencing and methylation analysis placed the lesion into the EMC class (0.99 score). Transcriptome cluster comparative analysis placed its expression profile close to pancreas neuroendocrine tumors. This case suggests NR4A2 as a functionally substitute for NR4A3 in tumorigenesis and a neuroendocrine lineage differentiation for a subset of EMC.
Indexed as
Identifiers
41315062What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.